黑色素瘤药物市场－全球产业规模、份额、趋势、机会和预测，依疗法、疾病类型、应用、地区和竞争格局划分，2020-2030年预测

全球黑色素瘤药物市场规模将从2024年的74.2亿美元成长到2030年的119.8亿美元，年复合成长率（CAGR）为8.31%。黑色素瘤药物是指用于治疗黑色素瘤（一种侵袭性皮肤癌）的药物，其作用机制是透过靶向并抑制恶性细胞的增殖和扩散。市场成长的主要驱动因素是全球黑色素瘤发生率的上升以及诊断技术的进步，使得疾病的早期检测成为可能。

主要市场驱动因素

全球黑色素瘤发生率的不断上升是推动黑色素瘤药物市场发展的重要因素。诊断病例的增加直接扩大了需要治疗的患者群体，从而推高了对有效疗法的需求。

主要市场挑战

创新黑色素瘤疗法的高昂成本严重阻碍了全球黑色素瘤药物市场的成长。新型标靶疗法和免疫疗法的高定价直接影响患者的治疗机会以及医疗保健系统的整体可持续性。

主要市场趋势

全球黑色素瘤药物市场的一个显着趋势是朝向多模式和联合疗法转变，这种疗法展现出更高的疗效和更佳的患者预后。该方法结合了不同的治疗方式，例如将免疫疗法与标靶药物结合，透过多种机制同时攻击癌细胞，从而克服抗药性并延长生存期。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球黑色素瘤药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗方法（化疗、免疫疗法、标靶治疗）
  • 依疾病类型（表浅扩散型黑色素瘤、恶性雀斑样痣、肢端雀斑样黑色素瘤、结节型黑色素瘤）
  • 依申请方式（医院、门诊肿瘤诊所、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美黑色素瘤药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲黑色素瘤药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区黑色素瘤药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲黑色素瘤药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美黑色素瘤药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球黑色素瘤药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co. Inc
• Abbott Laboratories Inc.
• Bayer AG
• Aptose Biosciences Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Melanoma Drugs Market will grow from USD 7.42 Billion in 2024 to USD 11.98 Billion by 2030 at a 8.31% CAGR. Melanoma drugs refer to pharmaceutical agents developed to treat melanoma, an aggressive form of skin cancer, by targeting and inhibiting the proliferation and spread of malignant cells. The market's growth is predominantly driven by the increasing global incidence of melanoma and advancements in diagnostic technologies enabling earlier disease detection.

Key Market Drivers

The increasing incidence of melanoma globally represents a fundamental driver for the melanoma drugs market. The rise in diagnoses directly expands the patient pool requiring therapeutic intervention, thereby escalating demand for effective treatments. According to the American Cancer Society, in February 2025, an estimated 104,960 new cases of invasive melanoma are expected to be diagnosed in the United States this year. This growing patient demographic underscores the urgent need for a continuous supply of both existing and novel pharmaceutical solutions. Factors such as increased ultraviolet radiation exposure and improved diagnostic capabilities contribute to these rising numbers, highlighting a persistent and evolving challenge in public health that fuels market expansion.

Key Market Challenges

The substantial cost associated with innovative melanoma treatments represents a significant impediment to the growth of the global melanoma drugs market. The high pricing of novel targeted therapies and immunotherapies directly impacts patient access and the overall sustainability of healthcare systems. This financial burden, often termed financial toxicity, can lead to reduced treatment initiation and adherence, even for life-extending medications.

Key Market Trends

A significant trend in the global melanoma drugs market is the shift towards multi-modal and combination therapies, which are demonstrating enhanced efficacy and improved patient outcomes. This approach involves combining different therapeutic modalities, such as immunotherapies with targeted agents, to attack cancer cells through multiple mechanisms simultaneously, thereby overcoming resistance and extending survival.

Key Market Players

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co. Inc
• Abbott Laboratories Inc.
• Bayer AG
• Aptose Biosciences Inc.

Report Scope:

In this report, the Global Melanoma Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Melanoma Drugs Market, By Therapy:

• Chemotherapy
• Immunotherapy
• Targeted Therapy

Melanoma Drugs Market, By Disease Type:

• Superficial Spreading Melanoma
• Lentigo Maligna
• Acral Lentiginous Melanoma
• Nodular Melanoma

Melanoma Drugs Market, By Application:

• Hospitals
• Outpatient Oncologist Clinics
• Others

Melanoma Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Melanoma Drugs Market.

Available Customizations:

Global Melanoma Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Melanoma Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy)
  • 5.2.2. By Disease Type (Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma, Nodular Melanoma)
  • 5.2.3. By Application (Hospitals, Outpatient Oncologist Clinics, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Melanoma Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Disease Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Melanoma Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Melanoma Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Melanoma Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Application

7. Europe Melanoma Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Disease Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Melanoma Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Application
  • 7.3.2. France Melanoma Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Melanoma Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Melanoma Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Melanoma Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Application

8. Asia Pacific Melanoma Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Disease Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Melanoma Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Application
  • 8.3.2. India Melanoma Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Melanoma Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Melanoma Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Melanoma Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Application

9. Middle East & Africa Melanoma Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Disease Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Melanoma Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Melanoma Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Melanoma Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Application

10. South America Melanoma Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Disease Type
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Melanoma Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Melanoma Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Melanoma Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Melanoma Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Amgen Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Johnson & Johnson
• 15.7. Merck & Co. Inc
• 15.8. Abbott Laboratories Inc.
• 15.9. Bayer AG
• 15.10. Aptose Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer